Starpharma Pty Limited

Lisa Michelle Kaminskas

Brian Devlin Kelly

Guy Yeoman Krippner

Benjamin James Boyd

Pasquale Razzino

Christopher John Hamilton Porter

Gottfried Lichti

Peter Karellas

Scott Andrew Henderson

Zemin Wu

Phillip Martin Rendle

Charlotte Claire Williams

Sue Pallich

Susanne Pallich

Angela Michelle Scheppokat

Ben William Greatrex

Christopher John Porter

The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.

Modified macromolecule

The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.

Macromolecular compounds having controlled stoichiometry

Growing community of inventors

Brunswick West, Australia

Lisa Michelle Kaminskas